Subtopic Deep Dive
BMPR2 Mutations in Pulmonary Arterial Hypertension
Research Guide
What is BMPR2 Mutations in Pulmonary Arterial Hypertension?
BMPR2 mutations are germline loss-of-function variants in the bone morphogenetic protein receptor type 2 gene that cause familial and idiopathic pulmonary arterial hypertension by disrupting TGF-β/BMP signaling and promoting pulmonary vascular proliferation.
BMPR2 mutations account for 70-80% of familial PAH cases and 15-25% of idiopathic PAH. These mutations lead to reduced BMPR2 expression, haploinsufficiency, and endothelial dysfunction. Over 800 BMPR2 mutations have been identified, with incomplete penetrance around 20%.
Why It Matters
BMPR2 mutations enable genetic screening for at-risk families, as recommended in ESC/ERS guidelines (Galiè et al., 2015, 6860 citations). They guide precision medicine by identifying therapeutic targets like BMP9 agonists to restore signaling. Survival prediction models incorporating BMPR2 status improve risk stratification in PAH (Benza et al., 2010, 1530 citations). Early detection via screening reduces diagnostic delays in high-risk groups (McGoon et al., 2004, 930 citations).
Key Research Challenges
Incomplete Penetrance
Only 20% of BMPR2 mutation carriers develop PAH, requiring identification of genetic modifiers. Environmental factors also influence phenotype expression (Humbert et al., 2018). ESC/ERS guidelines highlight need for penetrance studies (Galiè et al., 2009, 3842 citations).
Therapeutic Targeting
Loss-of-function mutations resist simple gene replacement due to dominant-negative effects. BMP agonists show promise but face delivery challenges in pulmonary vasculature (Thenappan et al., 2018). Guidelines note limited BMPR2-specific therapies (Galiè et al., 2015).
Genetic Screening Protocols
Optimal screening algorithms for family members remain undefined despite guideline recommendations. Cost-effectiveness varies by mutation prevalence (McGoon et al., 2004). Updated classifications emphasize genetic confirmation (Simonneau et al., 2018, 3690 citations).
Essential Papers
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Nazzareno Galiè, Marc Humbert, Jean-Luc Vachiéry et al. · 2015 · European Heart Journal · 6.9K citations
Document Reviewers: Victor Aboyans (CPG Review Coordinator) (France), Antonio Vaz Carneiro (CPG Review Coordinator) (Portugal), Stephan Achenbach (Germany), Stefan Agewall (Norway), Yannick Allanor...
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
Nazzareno Galiè, Marius M. Hoeper, Marc Humbert et al. · 2009 · European Heart Journal · 3.8K citations
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the Eu...
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Gérald Simonneau, David Montani, David S. Celermajer et al. · 2018 · European Respiratory Journal · 3.7K citations
Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measure...
Predicting Survival in Pulmonary Arterial Hypertension
Raymond L. Benza, Dave P. Miller, Mardi Gomberg‐Maitland et al. · 2010 · Circulation · 1.5K citations
Background— Factors that determine survival in pulmonary arterial hypertension (PAH) drive clinical management. A quantitative survival prediction tool has not been established for research or clin...
Guidelines for the diagnosis and treatment of pulmonary hypertension
Marius M. Hoeper, Marc Humbert, Adam Torbicki et al. · 2009 · European Respiratory Journal · 1.3K citations
Task force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology and the European Respiratory Society endorsed by the International Society of Heart and Lu...
Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives
Marc Humbert, Christophe Guignabert, Sébastien Bonnet et al. · 2018 · European Respiratory Journal · 1.2K citations
Clinical and translational research has played a major role in advancing our understanding of pulmonary hypertension (PH), including pulmonary arterial hypertension and other forms of PH with sever...
Pulmonary arterial hypertension: pathogenesis and clinical management
Thenappan Thenappan, Mark L. Ormiston, John Ryan et al. · 2018 · BMJ · 974 citations
Pulmonary hypertension is defined as a resting mean pulmonary artery pressure of 25 mm Hg or above. This review deals with pulmonary arterial hypertension (PAH), a type of pulmonary hypertension th...
Reading Guide
Foundational Papers
Start with Galiè et al. (2009, 3842 citations) for diagnostic framework including genetic testing, then Benza et al. (2010, 1530 citations) for survival models incorporating BMPR2, and McGoon et al. (2004, 930 citations) for screening protocols.
Recent Advances
Simonneau et al. (2018, 3690 citations) for updated PH classification with genetic emphasis; Humbert et al. (2018, 1198 citations) for BMPR2 pathobiology advances; Thenappan et al. (2018, 974 citations) for management integrating genetics.
Core Methods
Genetic: NGS panels, Sanger sequencing. Functional: BMPR2 expression via Western blot, signaling assays. Clinical: Right heart catheterization (mPAP ≥25 mmHg), risk calculators (REVEAL 2.0).
How PapersFlow Helps You Research BMPR2 Mutations in Pulmonary Arterial Hypertension
Discover & Search
Research Agent uses searchPapers('BMPR2 mutations PAH') to retrieve Galiè et al. (2015) guidelines (6860 citations), then citationGraph to map 500+ citing papers on screening protocols, and findSimilarPapers to uncover modifier studies linked to Humbert et al. (2018). exaSearch scans preprints for unpublished BMPR2 agonists.
Analyze & Verify
Analysis Agent applies readPaperContent on Benza et al. (2010) to extract survival predictors, verifyResponse with CoVe to confirm BMPR2 penetrance stats against guidelines, and runPythonAnalysis for Kaplan-Meier survival curves from REVEAL registry data using pandas/matplotlib. GRADE grading assesses evidence quality for screening recommendations.
Synthesize & Write
Synthesis Agent detects gaps in BMPR2 therapy trials via contradiction flagging across Galiè reviews, while Writing Agent uses latexEditText for manuscript revisions, latexSyncCitations to integrate 50+ PAH papers, latexCompile for PDF output, and exportMermaid for signaling pathway diagrams.
Use Cases
"Analyze survival data from REVEAL registry for BMPR2 mutation carriers"
Research Agent → searchPapers('Benza 2010 REVEAL') → Analysis Agent → readPaperContent + runPythonAnalysis (pandas cohort stratification, matplotlib Kaplan-Meier plots) → researcher gets CSV survival tables and verified hazard ratios.
"Write LaTeX review section on BMPR2 screening guidelines"
Synthesis Agent → gap detection (Galiè 2015 vs McGoon 2004) → Writing Agent → latexEditText('draft text') → latexSyncCitations(20 papers) → latexCompile → researcher gets camera-ready PDF with synced references.
"Find open-source code for BMPR2 signaling models in PAH"
Research Agent → searchPapers('BMPR2 computational model PAH') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets annotated Python scripts for TGF-β pathway simulations.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(100+ BMPR2 papers) → citationGraph clustering → GRADE evidence synthesis → structured report on mutation modifiers. DeepScan applies 7-step analysis with CoVe checkpoints to verify penetrance claims across Galiè guidelines. Theorizer generates hypotheses linking BMPR2 to survival predictors from Benza (2010) data.
Frequently Asked Questions
What defines BMPR2 mutations in PAH?
Germline loss-of-function mutations in BMPR2 gene causing haploinsufficiency and disrupted TGF-β/BMP signaling, underlying 70% familial and 20% idiopathic PAH cases.
What methods detect BMPR2 mutations?
Sanger sequencing or next-generation sequencing panels for PAH genes, with guidelines recommending cascade screening for family members (Galiè et al., 2015).
What are key papers on BMPR2 in PAH?
Galiè et al. (2015 ESC/ERS Guidelines, 6860 citations) standardizes screening; Benza et al. (2010, 1530 citations) links BMPR2 to survival prediction; Humbert et al. (2018) details pathobiology.
What open problems exist in BMPR2 PAH research?
Incomplete penetrance mechanisms, effective gene therapies for dominant-negative mutations, and validated screening algorithms for low-penetrance variants.
Research Pulmonary Hypertension Research and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching BMPR2 Mutations in Pulmonary Arterial Hypertension with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers